Brought to you by 
Hoth Therapeutics licenses UMB's RAMBAs to develop dermatology therapeutics
01 Apr 2020
Executive Summary
Hoth Therapeutics Inc. gets exclusive rights within dermatology to develop and commercialize retinoic acid metabolism blocking agents (RAMBAs) from the University of Maryland, Baltimore (UMB) and its spin-out company Isoprene Pharmaceuticals Inc.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hoth Therapeutics licenses UMB's RAMBAs to develop dermatology therapeutics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice